Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant

Cancers, Free Full-Text

Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial - ScienceDirect

ASCO GU 2023: EVOLUTION: Phase II Study of Radionuclide 177Lu-PSMA-617 Therapy Versus 177Lu-PSMA-617 in Combination with Ipilimumab and Nivolumab for Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC; ANZUP 2001)

Cancers, Free Full-Text

Long-term complete remission with ipilimumab in metastatic castrate- resistant prostate cancer: case report of two patients

ASCO GU 2019: Initial Results from a Phase II Study of Nivolumab plus Ipilimumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer - CheckMate 650

Nivolumab plus ipilimumab, with or without enzalutamide, in AR‐V7‐expressing metastatic castration‐resistant prostate cancer: A phase‐2 nonrandomized clinical trial - Shenderov - 2021 - The Prostate - Wiley Online Library

Figure 2 from Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.

Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-Resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial - Beyond the Abstract

IJMS, Free Full-Text

ASCO GU 2019: Initial Results from a Phase II Study of Nivolumab plus Ipilimumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer - CheckMate 650

Nivolumab Plus Ipilimumab Demonstrates Anti-Tumor Activity in Metastatic Castration-Resistant Prostate Cancer

PDF) Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond

Immunotherapy in Prostate Cancer: Recent Advances and Future Directions - European Medical Journal